[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Interleukin-33 inhibitors - Pipeline Insight, 2021

March 2021 | 60 pages | ID: IC4EB795F758EN

US$ 1,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
This report can be delivered to the clients within 24 hours

DelveInsight’s, “Interleukin-33 inhibitors - Pipeline Insight, 2021,” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Interleukin-33 inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Interleukin-33 inhibitors Understanding

Interleukin-33 inhibitors: Overview

IL-33 belongs to the IL-1 family of cytokines. IL-33 is a novel cytokine that signals through the ST2 surface receptor. IL-33 receptor has a single chain, which is also related to the IL-1 receptor (interleukin-1 receptor-like 1, IL-1RL1). Signal transduction upon ligand binding involves the Toll-like receptor (TIR) domain of the receptor chain and resembles that of IL-1 and IL-18, and TLRs. IL-33 exhibits diverse immune regulatory functions during the various phases of different diseases. IL-33 likely functions as a disease sensitizer and plays pathological roles in inflamed tissues in allergic disorders that involve hyperreactive immune responses. In contrast, IL-33 also mediates tissue-protective functions during the recovery phase following tissue injury, which involves activation of tissue-reparative M2 macrophages, ILC2s, and Tregs. IL-33 could be used against inflammation caused by Th1 response, and antagonists perhaps might be developed as anti-allergic compounds. Targeting the IL-33-ST2 axis using monoclonal antibodies (or small-molecule inhibitors) could prove to be an effective strategy against COVID-19 virus. The combination of IL-33 blockade with other therapeutics could be an option for the efficacious treatment of inflammatory diseases.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Interleukin-33 inhibitors R&D. The therapies under development are focused on novel approaches for Interleukin-33 inhibitors.
Interleukin-33 inhibitors Emerging Drugs Chapters

This segment of the Interleukin-33 inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Interleukin-33 inhibitors Emerging Drugs
  • MEDI3506: AstraZeneca
MEDI3506 is an IL-33 (interleukin-33) inhibiting monoclonal antibody being developed by AstraZeneca. The drug is currently in Phase II clinical studies for the treatment of COPD, atopic dermatitis, asthma, COVID-19 infection, and diabetic kidney disease.
  • Itepekimab: Regeneron Pharmaceuticals/Sanofi
Itepekimab (REGN3500) is a fully-human monoclonal antibody that inhibits interleukin-33. The drug is being studied in Phase III trials for asthma, chronic obstructive pulmonary disease. REGN3500 was invented using Regeneron's proprietary VelocImmune technology that yields optimized fully-human antibodies, and is being developed jointly by Regeneron and Sanofi as part of a global collaboration agreement.

Further product details are provided in the report…….

Interleukin-33 inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Interleukin-33 inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players working on Interleukin-33 inhibitors
There are approx. 7+ key companies which are developing the Interleukin-33 inhibitors. The companies which have their Interleukin-33 inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Regeneron Pharmaceuticals/Sanofi.
  • Phases
DelveInsight’s report covers around 7+ products under different phases of clinical development like
  • Late-stage products (Phase III and
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Interleukin-33 inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravaginal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Interleukin-33 inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Interleukin-33 inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Interleukin-33 inhibitors drugs.

Interleukin-33 inhibitors Report Insights
  • Interleukin-33 inhibitors Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Interleukin-33 inhibitors Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Scenario and Emerging Therapies:
  • How many companies are developing Interleukin-33 inhibitors drugs?
  • How many Interleukin-33 inhibitors drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for Interleukin-33 inhibitors?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Interleukin-33 inhibitors therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Interleukin-33 inhibitors and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • AstraZeneca
  • Regeneron Pharmaceuticals
  • Sanofi
  • Genentech
  • Cantargia
Key Products
  • MEDI3506
  • Itepekimab
  • Astegolimab
  • CAN-10
  • Research program: IL1RAP-targeting antibody therapeutics
Executive Summary
Interleukin-33 inhibitors: Overview
  Mechanism of Action
Pipeline Therapeutics
  Comparative Analysis
Therapeutic Assessment
  Assessment by Product Type
  Assessment by Stage and Product Type
  Assessment by Route of Administration
  Assessment by Stage and Route of Administration
  Assessment by Molecule Type
  Assessment by Stage and Molecule Type
Interleukin-33 inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
  Interleukin-33 inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Interleukin-33 inhibitors Collaboration Deals
  Company-Company Collaborations (Licensing / Partnering) Analysis
  Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
  Comparative Analysis
Itepekimab: Regeneron Pharmaceuticals/Sanofi
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
  Comparative Analysis
MEDI3506: AstraZeneca
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
  Comparative Analysis
Drug name: Company name
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
  Comparative Analysis
CAN-10: Cantargia
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
  Comparative Analysis
Interleukin-33 inhibitors Key Companies
Interleukin-33 inhibitors Key Products
Interleukin-33 inhibitors- Unmet Needs
Interleukin-33 inhibitors- Market Drivers and Barriers
Interleukin-33 inhibitors- Future Perspectives and Conclusion
Interleukin-33 inhibitors Analyst Views
Interleukin-33 inhibitors Key Companies


Table 1 Total Products for Interleukin-33 inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products


Figure 1 Total Products for Interleukin-33 inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

More Publications